Buzzetti R, Costa S. Commento metodologico a "Sustained benefit from ivacaftor…". Orizzonti FC, 2016;13(1):41-43
Articolo per rivista
-
-
Buzzetti R, Costa S. Commento metodologico a "Repeated nebulisation of non-viral CFTR gene…". Orizzonti FC, 2016;13(1):44-47
-
Buzzetti R. Comprendere e valutare gli studi clinici. Atti XIV Seminario di Primavera FFC, 2016;:5-10
-
Buzzetti R, Galici V. Commento metodologico a "Risk factorrs for the progression of Cystic Fibrosis…". Orizzonti FC, 2016;13(2):25-26
-
Buzzetti R, Galici V. Commento metodologico a "Evolution of lung function during the first year of life…". Orizzonti FC, 2016;13(2):27-30
-
Salvatore D, Buzzetti R, Mastella G. An overview of international literature from cystic fibrosis registries. Part 5: Update 2012-2015 on lung disease.. Pediatr Pulmonol. , 2016;51(11):1251-1263
-
Salvatore D, Buzzetti R, Mastella G.. Update of literature from cystic fibrosis registries 2012-2015. Part 6: Epidemiology, nutrition and complications.. Pediatr Pulmonol. , 2016 Sep 29. ;:-
-
Pontrelli G, De Crescenzo F, Buzzetti R, Calò Carducci F, Jenkner A, Amodio D, De Luca M, Chiurchiù S, Davies EH, Simonetti A, Ferretti E, Della Corte M, Gramatica L, Livadiotti S, Rossi P.. Diagnostic value of soluble triggering receptor expressed on myeloid cells in paediatric sepsis: a systematic review.. Ital J Pediatr. , 2016;:42-44
-
Buzzetti R. Le potenze del 10 e la potenza dell'acqua. Quaderni ACP, 2016;23(4):167-168
-
Buzzetti R, Salvatore D.. Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?. Am J Respir Crit Care Med., 2017;Feb 1;195(3):404-405
© 2022 Roberto Buzzetti - P. iva: 02926830163 - Developed by Onlime